Menu

Hesperidin

Also known as: Hesperetin-7-O-rutinoside, Hesperidin flavanone

A citrus flavanone with mixed vascular findings; measurable absorption is not proof of better circulation or fewer cardiovascular events.

Watercolor study of an orange half and curved peel with pale pith
Editorial illustration

Hesperidin is a citrus flavanone studied in oral preparations. A small metabolic-syndrome study found improved artery dilation, but later trials did not consistently reproduce a whole-group benefit. Detecting its metabolites after consumption does not establish disease prevention or a personal treatment dose.1, 2, 3

  • The 2011 crossover trial involved 24 participants with metabolic syndrome, not a general-population event-prevention trial.1
  • In 2016, 68 participants were randomized; whole-group flow-mediated dilation did not significantly improve.2
  • Thirty-seven centrally overweight men completed the 2026 three-period trial; metabolite exposure increased without an FMD benefit.3

What is Hesperidin?

The compound and its metabolite hesperetin are related, not interchangeable experimental exposures. The 2011 paper combined cell work using hesperetin with human supplementation using hesperidin. In 2026, orange juice and a hesperidin-enriched drink produced measurable flavanone exposure without detectable short-term vascular improvement.1, 3

Where it comes from

Natural sources

  • A flavanone glycoside in citrus foods, including orange juice

How it's made

A specified supplement or enriched drink is not automatically equivalent to a fruit serving, isolated hesperetin or a mixed flavonoid product.

What it does in products

  • Flavanone ingredient in studied oral supplements and enriched drinks

Benefits

A vascular signal with inconsistent replication

limited evidence

An early positive endothelial-function finding does not establish a dependable benefit across populations.1, 2, 3

The 2011 trial was small and short. The 2016 trial had no significant total-population FMD benefit, and its favorable subgroup analyses were exploratory and unadjusted for multiplicity. The 2026 trial also found no fasting or post-meal FMD improvement versus control. These are surrogate outcomes, not heart-attack prevention trials.

Evidence scope and limitations

Three illustrative oral vascular trials and general U.S. supplement guidance; not a comprehensive review of every hesperidin indication or a flavonoid-combination assessment.

  • Small, short trials with surrogate endpoints cannot establish prevention of clinical cardiovascular events.
  • Population, stereoisomer formulation, food matrix and exposure differ between trials.
  • The 2016 indexed primary abstract and the 2026 primary abstract were checked; unseen full-text safety details are not inferred.

Evidence last checked: 2026-10-16

Side effects & safety

Incomplete adverse-event information for personal risk assessment (varies)The available short trial reports do not establish a comprehensive long-term adverse-effect rate. Lack of a prominent harm statement in an abstract is not evidence that every dose or combination is safe.

Safety considerations

  • The selected trials do not define a complete interaction profile. FDA advises professional discussion before supplement use, particularly when medicines or medical conditions are involved.
  • Not for: These selected adult studies do not establish a pregnancy, breastfeeding or pediatric supplement regimen.
  • Not for: Do not replace prescribed cardiovascular treatment with a biomarker or flavanone-absorption finding.
1, 2, 3, 5

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In supplement studies and products

The selected studies used 500 mg/day for three weeks (2011), 450 mg/day hesperidin 2S for six weeks (2016), and 210 mg/day in an enriched control beverage during six-week periods (2026). These are distinct research exposures, not a recommended range or a conversion from orange servings to capsules.

1, 2, 3

Regulatory status

  • U.S. supplement manufacturers are responsible for safety and truthful labeling under a framework different from drugs. A clinical publication or the presence of the compound in food does not establish FDA approval for a cardiovascular treatment.
4

Exposure is a step in the pathway, not the destination

The recent trial helps separate delivery from outcome: comparable flavanone exposure after juice and an enriched drink did not yield a detectable vascular effect. It would be misleading to use the absorption finding as a substitute for the negative primary endpoint.

The older positive study and later null findings also involved different populations and preparations. They justify continued research, not a claim that one study proves all citrus products effective or that a null result establishes absolute biological inactivity.

3, 1, 2

Frequently asked questions

Does a positive result in endothelial cells prove a supplement benefit?

No. The 2011 cellular experiment used hesperetin; its human trial was a separate experiment. A mechanism does not supply an event-prevention outcome.1

Can the favorable 2016 subgroup replace the total study result?

No. Its exploratory analyses were not adjusted for multiplicity; the total population did not show the claimed FMD improvement.2

The bottom line

Match the preparation and population, and ask for the clinical endpoint rather than treating absorption or a subgroup as the final benefit.

References

  1. Rizza S, Muniyappa R, Iantorno M, et al.. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. Journal of Clinical Endocrinology & Metabolism (2011) · randomized trial · PMID 21346065; DOI 10.1210/jc.2010-2879; original clinical abstract and cellular-versus-human design checked
  2. Salden BN, Troost FJ, de Groot E, et al.. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. American Journal of Clinical Nutrition (2016) · randomized trial · PMID 27797708; DOI 10.3945/ajcn.116.136960; NCT02228291; indexed primary abstract checked; exploratory analyses unadjusted for multiplicity
  3. Gilcher C, Milenkovic D, Taillandier M, et al.. Orange juice and hesperidin increase flavanone exposure without detectable short-term vascular benefits: a randomized crossover trial. Food & Function (2026) · randomized trial · PMID 42605853; DOI 10.1039/d6fo02778d; published September 1, 2026; primary abstract checked
  4. Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated agency resource; manufacturer safety and labeling responsibilities checked October 16, 2026
  5. Dietary Supplements: Consumer Updates. U.S. Food and Drug Administration · government guidance · Undated agency resource; professional-consultation and interaction cautions checked October 16, 2026

Revision history

  1. Initial AI-assisted source checks and claim-level citation mapping under the site-authorized publishing workflow. No separate human or independent medical review is claimed.